Skip to main content
Fig. 2 | Skeletal Muscle

Fig. 2

From: Treatment with the anti-IL-6 receptor antibody attenuates muscular dystrophy via promoting skeletal muscle regeneration in dystrophin-/utrophin-deficient mice

Fig. 2

IL-6 levels in serum and the quadriceps muscle. a Serum IL-6 levels of mice at 90 days of age. Serum IL-6 levels of MR16-1-treated dKO mice were increased by about fourfold compared with the rat IgG group. b IL-6 levels of the quadriceps muscle (QF) of dKO mice treated with rat IgG or MR16-1. IL-6 levels were relatively lower in MR16-1-treated dKO mice (P = 0.12). c Quantitative RT-PCR analysis of the levels of Il-6, Il-6ra, Il-6se, Socs3, and Stat3 were measured. All samples were normalized to the expression levels of Lbr. Values of rat IgG and MR16-1 groups were expressed as fold increase of wild-type mice (n = 3–4 per group). d A representative image of Western blot analysis of phosphorylated STAT3 (pSTAT3), total STAT3, and GAPDH. e The expression of pSTAT3 normalized by total STAT3 levels in dKO mice treated with rat IgG or MR16-1 (n = 6 per group). Activated STAT3 levels were significantly decreased in dKO mice by MR16-1 treatment. *P < 0.05, **P < 0.01, ***P < 0.001

Back to article page